Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 6/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.40 |
| ▸ | AXL | P30530 | 5/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.40 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.40 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.40 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.39 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.39 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.39 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CCND1 | P24385 | 1/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15041494 | 0.80 | JAK2 (0.46) | FGFR1AXLFGFR2FGFR4FGFR3 | |
| SCHEMBL15041499 | 0.74 | CAMK2D (0.40) | SRCFGFR1AXLPDGFRBTNK2 | |
| SCHEMBL15041896 | 0.73 | TNK2 (0.39) | SRCTNK2CAMK2DPAK4PKN1 | |
| SCHEMBL15041506 | 0.73 | RIPK2 (0.42) | SRCFGFR1AXLTNK2CAMK2D | |
| SCHEMBL13553504 | 0.72 | CAMK2D (0.40) | SRCFGFR1AXLTNK2FGFR2 | |
| SCHEMBL15041887 | 0.72 | FGFR1 (0.38) | SRCFGFR1PDGFRBPDGFRAFGFR4 | |
| SCHEMBL15035114 | 0.72 | PAK4 (0.40) | SRCFGFR1AXLPDGFRBTNK2 | |
| SCHEMBL14682085 | 0.71 | PKN1 (0.63) | SRCFGFR1PDGFRBPDGFRASLC2A1 | |
| SCHEMBL15041858 | 0.71 | TNK2 (0.41) | SRCFGFR1TNK2CAMK2DPAK4 | |
| SCHEMBL15785236 | 0.71 | PAK4 (0.43) | SRCFGFR1AXLPDGFRBTNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912203-B2 | 6-(sulfonylaryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders | AFRAXIS HOLDINGS, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | SRC 26/4885FGFR1 1919/4885AXL 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.